

## Overview

### Useful For

Aiding in the diagnosis of infection with *Cryptococcus neoformans* or *C gattii*

### Highlights

Detection of *Cryptococcus* antigen in urine may be used as an adjunct method for diagnosis of disseminated infection with *Cryptococcus neoformans/gattii*, alongside culture and other serologic methods (eg, *Cryptococcus* antigen testing on serum or cerebrospinal fluid).

A negative result should not be used to rule-out infection.

### Reflex Tests

Test ID	Reporting Name	Available Separately	Always Performed
ULFAT	Cryptococcus Ag Titer, LFA, U	No	No

### Testing Algorithm

If this screen is positive, the antigen titer will be performed at an additional charge.

### Method Name

Lateral Flow Assay (LFA)

### NY State Available

Yes

## Specimen

### Specimen Type

Urine

### Specimen Required

**Supplies:** Urine Tubes, 10 mL (T068)

**Submission Container/Tube:** Plastic, 10-mL urine tube

**Specimen Volume:** 1 mL

### Collection Instructions:

1. Collect a random urine specimen.
2. No preservative.

### Specimen Minimum Volume

0.5 mL

**Reject Due To**

Gross hemolysis	Reject
Other	Turbid reject; Colored reject

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Urine	Refrigerated (preferred)	14 days	
	Frozen	14 days	

**Clinical and Interpretive**
**Clinical Information**

Cryptococcosis is an invasive fungal infection caused by *Cryptococcus neoformans* or *C gattii*. The organism has been isolated from several sites in nature, particularly weathered pigeon droppings.

Infection is usually acquired via the pulmonary route. Patients are often unaware of any exposure history. Approximately half of the patients with symptomatic disease have a predisposing immunosuppressive condition such as AIDS, steroid therapy, lymphoma, or sarcoidosis. Symptoms may include fever, headache, dizziness, ataxia, somnolence, and cough. While the majority of *C neoformans* infections occur in immunocompromised patient populations, *C gattii* has a predilection for infection of healthy hosts.

In addition to the lungs, cryptococcal infections frequently involve the central nervous system (CNS), particularly in HIV-infected patients. Mortality associated with CNS cryptococcosis approaches 25% despite antifungal therapy, while untreated CNS cryptococcosis is invariably fatal. Disseminated disease may affect any organ system and usually occurs in immunosuppressed individuals.

**Reference Values**

Negative

Reference values apply to all ages.

**Interpretation**

The presence of cryptococcal antigen (CrAg) in any body fluid is strongly suggestive of infection with *Cryptococcus neoformans* or *C gattii*.

Declining titers are suggestive of clinical response to therapy. However, monitoring CrAg titers should not be used as a test of cure, as low level titers may persist for extended periods of time following appropriate therapy and disease resolution.

In addition to testing for CrAg, patients with presumed disease due to *C neoformans* or *C gattii* should have appropriate clinical specimens (eg, blood, bronchoalveolar lavage fluid) submitted for routine smear and fungal culture.

**Cautions**

[A negative result does not preclude the diagnosis of cryptococcosis, particularly if only a single specimen has been](#)

[tested and the patient shows symptoms consistent with cryptococcal infection.](#)

A positive result is suggestive of cryptococcosis, however, all test results should be interpreted in light of other clinical findings.

Testing should not be performed as a screening procedure for the general population and should only be performed when clinical evidence suggests the cryptococcal disease.

Although rare, extremely high concentrations of cryptococcal antigen (CrAg) can result in weakly positive or falsely-negative results.

Patients with trichosporonosis or *Capnocytophaga* species infection may yield false-positive results.

If followed for clinical purposes, CrAg titers should be followed using the same assay.

### Clinical Reference

1. Hazen KC, Howell SA: Candida, Cryptococcus, and other Yeasts of Medical Importance. In Manual of Clinical Microbiology. Ninth edition. Edited by PR Murray. Washington, DC, ASM Press, 2007, pp 1762-1788
2. Bruner KT, Franco-Paredes C, Henao-Martinez A, et al: Cryptococcus gattii Complex Infections in HIV-Infected Patients, Southeastern United States. EID 2018 Nov;24(11) doi.org/10.3201/eid2411.180787

### Performance

#### Method Description

The *Cryptococcus* antigen (CrAg) lateral flow assay is a sandwich immunochromatographic assay. Specimens and diluent are added to a test tube and the lateral flow device is added. The test uses specimen wicking to capture gold-conjugated anticryptococcal antigen monoclonal antibodies and gold-conjugated control antibodies deposited on the test membrane. If cryptococcal antigen is present in the specimen, it binds to the gold-conjugated anticryptococcal antigen antibodies. This complex wicks up the membrane and interacts with the test line, which has immobilized anticryptococcal antigen monoclonal antibodies. The antigen-antibody complex forms a sandwich at the test line causing a visible line to form. A valid test shows a visible line at the control line. Positive test results create 2 lines (control and specimen), while negative results form only the control line. (Package insert: CrAg Lateral Flow Assay, IMMY, Norman, OK, Rev 2012)

#### PDF Report

No

#### Day(s) and Time(s) Test Performed

Monday through Friday; Variable

#### Analytic Time

1 day

#### Maximum Laboratory Time

2 days

#### Specimen Retention Time

7 days/1 week

#### Performing Laboratory Location

Rochester

**Fees and Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

**Test Classification**

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**CPT Code Information**

87899-Cryptococcus Ag Screen, LFA, U

87899-Cryptococcus Ag Titer, LFA, U (if appropriate)

**LOINC® Information**

Test ID	Test Order Name	Order LOINC Value
ULFA	Cryptococcus Ag Screen, LFA, U	16693-4

Result ID	Test Result Name	Result LOINC Value
604095	Cryptococcus Ag Screen, LFA, U	16693-4